Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 11/20 | 0.50 |
| ▸ | NQO2 | P16083 | 2/20 | 0.41 |
| ▸ | CASR | P41180 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.33 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18803135 | 0.88 | GRM2 (0.46) | GRM2NQO2CASRMAPTBRD9 | |
| SCHEMBL20268944 | 0.79 | GRM2 (0.41) | GRM2NQO2CASRMAPTBRD9 | |
| SCHEMBL16475171 | 0.74 | GRM2 (0.42) | GRM2 | |
| SCHEMBL25285360 | 0.72 | SLC9A1 (0.40) | GRM2NQO2MAPTSLC9A1 | |
| SCHEMBL16475169 | 0.71 | GRM2 (0.42) | GRM2 | |
| SCHEMBL26654800 | 0.67 | GRM2 (0.55) | GRM2MAPTSLC9A1 | |
| SCHEMBL30665857 | 0.67 | GRM2 (0.55) | GRM2MAPTSLC9A1 | |
| SCHEMBL2498265 | 0.66 | CASR (0.79) | CASR | |
| SCHEMBL18323572 | 0.66 | GRM2 (0.42) | GRM2BRD9SLC9A1 | |
| SCHEMBL16831208 | 0.66 | GRM2 (0.63) | GRM2MAPTSLC9A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170121345-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2017-05-04 | — | — | US | disclosed |
| US-20170121345-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121345-A1 | ANTI-FIBROTIC PYRIDINONES | MMP1, COL1A1, COL2A1 | GRM2 4047/4885NQO2 2860/4885CASR 3999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.